Activation of RAS family members confers resistance to ROS1 targeting drugs

The ROS1 tyrosine kinase is activated in lung cancer as a consequence of chromosomal rearrangement. Although high response rates and disease control have been observed in lung cancer patients bearing rearranged ROS1 tumors (ROS1+) treated with the kinase inhibitor crizotinib, many of these patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Cargnelutti, Marilisa, Corso, Simona, Pergolizzi, Margherita, Mévellec, Laurence, Aisner, Dara L., Dziadziuszko, Rafal, Varella-Garcia, Marileila, Comoglio, Paolo M., Doebele, Robert C., Vialard, Jorge, Giordano, Silvia
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467141/
https://ncbi.nlm.nih.gov/pubmed/25691052
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky